Eli Lilly (LLY) and Novo Nordisk (NVO) stocks surged in retail chatter after reports of TrumpRx deals to cut US weight-loss drug prices in exchange for Medicare coverage. The agreements, following Pfizer and AstraZeneca, could expand reimbursement and access. Retail sentiment was extremely bullish, with traders eyeing LLY at $920 and an NVO rebound.